Temozolomide plus radiotherapy for glioblastoma in a Canadian province: Efficacy versus effectiveness and the impact of O6-methylguanine-DNA- methyltransferase promoter methylation

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 2, 2012, Pages 229-238

  Lam, Nadine ^a   Chambers, Carole R ^a  

^a ALBERTA HEALTH SERVICES   (Canada)

Author keywords

Canada; glioblastoma; MGMT; O6 methylguanine DNA methyltransferase; radiotherapy; Temozolomide

Indexed keywords

CORTICOSTEROID; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; CANADA; CANCER RADIOTHERAPY; CLINICAL PRACTICE; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DNA METHYLATION; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PANCYTOPENIA; PATIENT SELECTION; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ALBERTA; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871794056     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211426198     Document Type: Article

References (35)

1. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001 ; 2 (9). 552-560
2. Alberta Provincial CNS Tumour Team. 'Glioblastoma', http://www. albertahealthservices.ca/hp/if-hp-cancer-guide-cns001-glioblastoma.pdf (2010, accessed 10 September 2010).
3. DeAngelis LM. Brain tumors. N Engl J Med. 2001 ; 344: 114-123
4. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003 ; 30 (Suppl. 19). 10-14
5. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993 ; 85: 704-710
6. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain. 2007 ; 130: 2596-2606
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 ; 352: 987-996
8. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002 ; 359: 1011-1018
9. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. JClin Oncol. 2002 ; 20: 1375-1382
10. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma - look to the future. Nat Clin Pract Oncol. 2008 ; 5: 476-486
11. Mason WP, Maestro RD, Eisenstat D, Forsyth P, Fulton D, Laperrière N, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007 ; 14: 110-117
12. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, et al. Central nervous system cancers. JNatl Compr Canc Netw. 2011 ; 9: 352-400
13. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004 ; 10: 1871-1874
14. Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, et al. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One. 2011 ; 6: e17156 - e17156
15. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009 ; 15: 6683-6693
16. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 ; 352: 997-1003
17. Hamilton MG, Roldán G, Magliocco A, McIntyre JB, Parney I, Easaw JC. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol. 2011 ; 102: 255-260
18. Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 ; 21 (Suppl. 5). v190 - v193
19. Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Buyukberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori. 2009 ; 95: 191-197
20. Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, et al. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg. 2009 ; 111: 679-682
21. Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F, et al. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol. 2010 ; 136: 1691-1695
22. Van Genugten JAB, Leffers P, Baumert BG, Tjon-a-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol. 2010 ; 96: 249-257
23. Herbert C, Williams M, Sawyer H, Greenslade M, Cornes P, Hopkins K. Treatment of glioblastoma multiforme with radiotherapy and concomitant and adjuvant temozolomide: translation of randomized controlled trial evidence into routine clinical practice. Clin Oncol (R Coll Radiol). 2011 ; 23: 372-373
24. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990 ; 8: 1277-1280
25. Hart MG, Grant R, Metcalfe SE. Biopsy versus resection for high grade glioma. Cochrane Database of Systematic Reviews. 2000 ; 2: CD002034 - CD002034
26. Tsitlakidis A, Foroglou N, Venetis CA, Patsalas I, Hatzisotiriou A, Selviaridis P. Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis. J Neurosurg. 2010 ; 112: 1020-1032
27. Taylor M, Chambers A, Perry J, Bernstein M.. Evidence-based review of the role of surgery for malignant glioma. Current Oncol. 2004 ; 11: 53-62
28. Proescholdt MA, Macher C, Woertgen C, Brawanski A. Level of evidence in the literature concerning brain tumor resection. Clin Neurol Neurosurg. 2005 ; 107: 95-98
29. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 ; 7: 392-401
30. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999 ; 42: 227-231
31. Quigley MR, Maroon JC. The relationship between survival and the extent of resection in patients with supratentorial malignant gliomas. Neurosurgery. 1991 ; 29: 385-389
32. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008 ; 9: 29
33. Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos MC. Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases. Br J Neurosurg. 2007 ; 21: 496-500
34. Wen PY, Kesari SK. Malignant gliomas in adults. N Engl J Med. 2008 ; 359: 492-507
35. Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 2007 ; 68: 688-690